Previous explorations have shown that CD93 is significantly upregulated and plays an important role in tumor vasculatures of renal cell carcinomas (Masiero et al. 2013), pancreatic adenocarcinoma (Sun et al. 2021b), nasopharyngeal carcinoma (Bao et al. 2016) and colon cancer (Olsen et al. 2015), which made it a probable antiangiogenic target for these cancers (Barbera et al. 2021; Orlandini et al. 2014; Sun et al. 2021b). This evidence concerns the gene CD93 and neoplasm.